$127.10
2.091.67%
At Close: -
$127.10
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Latest news for Sarepta Therapeutics (NASDAQ:SRPT) Stock
Sarepta Therapeutics Stock (NASDAQ: SRPT)
Categories: All
Thursday, September 19, 2024
Wednesday, September 18, 2024
Friday, September 06, 2024
Tuesday, September 03, 2024
Friday, August 16, 2024
Thursday, August 15, 2024
Monday, August 12, 2024
Sunday, August 11, 2024
Friday, August 09, 2024
Thursday, August 08, 2024
- RBC Capital Maintains Outperform on Sarepta T...
- Smart Money Is Betting Big In SRPT Options
- Citigroup Maintains Neutral on Sarepta Therap...
- Cantor Fitzgerald Maintains Neutral on Sarept...
- Evercore ISI Group Upgrades Sarepta Therapeut...
- Barclays Maintains Overweight on Sarepta Ther...
- McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- Sarepta Therapeutics shares are trading lower...
- Piper Sandler Maintains Overweight on Sarepta...
Wednesday, August 07, 2024
Monday, July 29, 2024
Thursday, July 18, 2024
Wednesday, July 17, 2024
Thursday, July 04, 2024
Monday, July 01, 2024
Thursday, June 27, 2024
Wednesday, June 26, 2024
Monday, June 24, 2024
- Here's How Much You Would Have Made Owning Sarepta Therapeutics Stock In The Last 10 Years
- Morgan Stanley Maintains Overweight on Sarept...
- Sarepta Therapeutics shares are trading highe...
- Evercore ISI Group Maintains In-Line on Sarep...
- Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
- BMO Capital Maintains Outperform on Sarepta T...
- Leerink Partners Maintains Outperform on Sare...
Sunday, June 23, 2024
Friday, June 21, 2024
- Growth Stocks Leave Value Stocks In The Dust: 4 Reasons For Biggest Monthly Lead In Over A Year
- Nasdaq Moves Lower; FactSet Research Posts Upbeat Earnings
- Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Morgan Stanley Reiterates Overweight on Sarep...
- Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
- Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?
- Piper Sandler Maintains Overweight on Sarepta...
- Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says